Financing ·
Enliven Therapeutics, Inc. entered into an underwriting agreement on June 11, 2026, to issue and sell 8,933,334 shares…
ELVNEnliven Therapeutics, Inc.
Enliven Therapeutics, Inc. entered into an underwriting agreement on June 11, 2026, to issue and sell 8,933,334 shares of common stock at $37.50 per share and 1,733,333 pre-funded warrants at $37.499 per warrant. The offering is expected to close on June 15, 2026, with expected net proceeds of approximately $376.0 million, potentially increasing to $432.4 million if underwriters exercise their option to purchase an additional 1,600,000 shares. Enliven Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer and other diseases.